joining us is hans schikan. hans, greet have you with us.r your time. >> thanks for the invitation. it's great to be on your show. >> a lot of analysts are now saying that this delay on the part of sarepta's drug is going to put you six months ahead. can you give us a time frame in terms of the next approval or the next submission process with the fda and when possible approval would be? >> well, let me start by saying we are all in this together. i mean, the american companies pioneering in rare diseases, very few in muscular dystrophy. the company working in the field, research groups, the patient organizations, the experts, any setback for anyone is a setback for this whole community. so my empathy goes to sarepta and to the patients who are eagerly waiting to be treated as well. but now about prosensa. we have started our submission process. and as a matter of fact on the 10th of october we submitted under a so-called rolling review. a rolling submission, our first models of our new drug application. that is possible because we have a so